Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2614800 | 0.89 | CA9 (0.44) | CA9CA12CA1CA2TSHR | |
| SCHEMBL16473964 | 0.89 | CA9 (0.44) | CA9CA12CA1CA2TSHR | |
| SCHEMBL20225549 | 0.85 | CA9 (0.39) | CA9CA12CA1CA2TSHR | |
| SCHEMBL10819148 | 0.83 | CA9 (0.38) | CA9CA12CA1CA2TSHR | |
| SCHEMBL26499249 | 0.82 | CA9 (0.40) | CA9CA12CA1CA2TSHR | |
| SCHEMBL17281224 | 0.82 | CA9 (0.40) | CA9CA12CA1CA2TSHR | |
| SCHEMBL26243889 | 0.82 | CA9 (0.40) | CA9CA12CA1CA2TSHR | |
| SCHEMBL19588718 | 0.82 | CA9 (0.33) | CA9CA12CA1CA2 | |
| SCHEMBL10819164 | 0.81 | OGA (0.38) | CA9CA12CA1CA2TSHR | |
| SCHEMBL17281225 | 0.81 | CA9 (0.39) | CA9CA12CA1CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155677-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEAGEN INC. | 2018-06-07 | — | — | US | disclosed |
| US-9816069-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | SEATTLE GENETICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20150337259-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEAGEN INC. | 2015-11-26 | — | — | US | disclosed |
| US-8993326-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | SEATTLE GENETICS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140031536-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEATTLE GENETICS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8574907-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | SEATTLE GENETICS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120183997-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEATTLE GENETICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031536-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | FUT5, FUCA2, FCGR3B | CA9 448/4885CA12 253/4885CA1 1064/4885 |
| US-20180155677-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | FUT5, FUCA2, FCGR3B | CA9 448/4885CA12 253/4885CA1 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.